Évaluation médico-économique, comparative en vie réelle de la morbi-mortalité post-traitement par résection endoscopique par DISsection sous muqueuse vers COlectomie dans le traitement des grandes lésions coliques superficielles en France (DISCO)

Study identification

• EU PAS number:
  EUPAS1000000919
• Study ID:
  1000000919
• Official title and acronym:
  Évaluation médico-économique, comparative en vie réelle de la morbi-mortalité post-traitement par résection endoscopique par DISsection sous muqueuse vers COlectomie dans le traitement des grandes lésions coliques superficielles en France (DISCO)
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  Colorectal cancer is the third most common cancer in France and the second most common in terms of mortality. As a possible alternative to surgery (colectomy), large polyps (>2 cm) can benefit from minimally invasive endoscopic resection techniques such as submucosal dissection. ; ; The main objective is to evaluate the real-life efficiency at 2 years, based on a cost/effectiveness analysis expressed in cost per life year gained, of endoscopic resection using submucosal dissection versus laparoscopic colectomy in the treatment of large superficial colonic lesions from the perspective of the French healthcare system. ; ; The DISCO study is based on SNDS data linked to data from the FECCo registry, which includes all individuals who have undergone Endoscopic Submucosal Dissection. The study period includes patients from 2019 with follow-up until 2024. The DISCO study is designed under the Target Trial Emulation framework.; ; If submucosal dissection is shown to be more effective than colectomy, offering monobloc endoscopic resection by this approach for benign lesions or superficial colorectal cancers would avoid major surgery, thereby limiting scarring and speeding up recovery. This would thus improve patients' quality of life and reduce the costs associated with hospitalization, time off work, and the management of complications.
• Study status:
  Planned

Research institutions and networks

Institutions

Bordeaux University Hospital (CHU de Bordeaux)

France

Bordeaux PharmacoEpi, University of Bordeaux

France

Study timelines

Date when funding contract was signed

Planned:30/06/2026

Study start date

Planned:01/01/2027

Data analysis start date

Planned:01/01/2027

Date of final study report

Planned:31/03/2028

Sources of funding

Other public funding (e.g. hospital or university)

More details on funding

PRME

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable